Clinical evidence dossier
Semaglutide
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 11
- Supporting studies available for review
- 11
- Randomized trials
- 10
- Reported effects
- 25
Clinical conclusion
Semaglutide shows a strong positive evidence signal for improving HbA1c across the studied comparisons.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Mean difference
-2.47 to -1.2 %
Change from baseline
Mean difference
-11 to -2 mmol/mol
Between-group effect
Mean difference
-0.3 to -0.3 percentage points
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 1
- Magnitude-eligible effects
- 14
Consistency
Authoritative consistency classification
consistent
- Positive
- 9
- No effect
- 2
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 11 of 11 supporting studies. 10 studies described participants with type 2 diabetes. 11 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults with type 2 diabetes inadequately controlled on metformin.
- Patients seeking affordable diabetes treatment options.
- Young Adult (19–39)
- Middle Aged (40-64)
- Male
- Female
- with T2 Diabetes
- Adults with type 2 diabetes seeking weight management options.
- Patients currently prescribed semaglutide or considering its use.
- Indian adults aged 18 and older with Type 2 diabetes.
- Individuals seeking effective management options for diabetes.
- Korean adults aged 18-75 with type 2 diabetes.
Limitations
- 1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.
- 2 supporting studies do not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: active_comparator, placebo, usual_care.
- 4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.
- 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.